AARTIPHARM vs NGLFINE: Stock Comparison

AARTI PHARMALABS vs NGL FINE CHEMUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

AARTI PHARMALABS is the larger company by market capitalisation. AARTI PHARMALABS shows a higher dividend yield and a higher net margin, while NGL FINE CHEM shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

AARTIPHARM leads 4; NGLFINE leads 9 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

AARTIPHARMNGLFINE

Valuation lens

What price are you paying?

Market CapContext only
₹7,812 Cr
₹1,804 Cr
P/E RatioNGLFINE has the lower reading
36.83x
30.41x
P/B RatioAARTIPHARM has the lower reading
3.71x
5.28x
EPSNGLFINE has the higher reading
₹8.4
₹29.78
Book ValueContext only
₹234.3
₹532.9
Dividend YieldAARTIPHARM has the higher reading
0.46%
0.07%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
AARTIPHARM is the larger company
₹7,812 Cr vs ₹1,804 Cr
P/E Ratio
NGLFINE has a lower P/E
30.41x vs 36.83x
P/B Ratio
AARTIPHARM has a lower P/B
3.71x vs 5.28x
EPS
NGLFINE has higher earnings per share
₹29.78 vs ₹8.4
Dividend Yield
AARTIPHARM has a higher dividend yield
0.46% vs 0.07%
Revenue Growth (TTM YoY)
NGLFINE has faster revenue growth
57.2% vs 3.3%
EPS Growth (TTM YoY)
NGLFINE has faster EPS growth
1,539.8% vs -30.8%
Qtr Sales Growth
NGLFINE has stronger quarterly sales growth
1.79% vs 0.23%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricAARTIPHARMNGLFINE
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricAARTIPHARMNGLFINE
Live Price₹858.8₹2,907.5
Day Change-1.07%-1.13%
Volume4.63 L7,107
52-Week High₹946.1₹3,602
52-Week Low₹585₹1,271
Distance from 52W High-9.23%-19.28%

Valuation

MetricAARTIPHARMNGLFINE
Market Cap₹7,812 Cr₹1,804 Cr
P/E Ratio36.83x30.41x
P/B Ratio3.71x5.28x
EPS₹8.4₹29.78
Book Value₹234.3₹532.9
Dividend Yield0.46%0.07%

Growth

MetricAARTIPHARMNGLFINE
Revenue Growth (TTM YoY)3.3%57.2%
EPS Growth (TTM YoY)-30.8%1,539.8%
Qtr Sales Growth0.23%1.79%
Qtr Profit Growth6.78%11.83%

Profitability & Leverage

MetricAARTIPHARMNGLFINE
ROE9.48%13.01%
ROCE8.38%10.54%
Net Margin10.25%9.59%
Operating Margin16.52%12.08%
Debt to Equity0.35x0.34x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricAARTIPHARMNGLFINE
Promoter Holding42.69% 0.22 pp72.49% 0.25 pp
FII Holding8.17% 0.22 pp0.05% 0.02 pp
DII Holding7.22% 0.19 pp0.02% 0.02 pp
Public Holding41.74% 0.63 pp27.43% 0.19 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: AARTI PHARMALABS and NGL FINE CHEM.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.